FDA has approved GLOPERBA, a prescription oral solution of colchicine, manufactured by Scilex Pharmaceuticals Inc. The product is identified by the brand name GLOPERBA, generic name colchicine, and NDC 69557-222-01.
The original NDA (210942) was approved in 2019 as a new dosage form. Subsequent submissions included a CMC supplement in 2021 and an efficacy supplement in 2024, both of which were approved by the agency.
The solution contains colchicine at a strength of 0.6 mg per 5 mL and is intended for oral administration. FDA submission documents include labeling, letters, and medication guides, with the most recent label dated September 2, 2024.
Regulatorische Updates24. Sept. 2026•1 Min. Lesezeit
FDA Approves GLOPERBA Oral Colchicine Solution (NDA 210942)
Scilex Pharmaceuticals' GLOPERBA, an oral colchicine solution (0.6 mg/5 mL), received FDA approval under NDA 210942, with supplemental updates in 2021 and 2024.
Zusammengestellt vom PharmaCountry-Team · Quelle: FDA.gov
Bewertungen
(0)
(0)
(0)
(0)
(0)
Weitere Artikel
Alle Einblicke anzeigenStudien & Berichte
Global Finished Dosage Manufacturing Landscape 2026
5. Okt. 2026
Regulatorische UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28. Sept. 2026
AnalysePharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28. Sept. 2026
Bewertung hinterlassen